Inotiv, Inc. Provides Business Updates
Inotiv, a leading contract research organization (CRO), has completed its Hillcrest, U.K. expansion project. This expansion allows two new customers to start their long-term contracts and enables the transfer of operations from the Blackthorn facility to Hillcrest by September 2024.
Inotiv has also extended the maturity date of its $3.7 million OBRC payable note to July 2025, which will start accruing interest at 4.6% per annum from July 2024. CEO Robert Leasure Jr. highlighted these steps as part of the company's transformation plan initiated in 2022, focusing on growth, efficiency, and improvements in infrastructure and animal welfare.
The company aims to ramp up sales and marketing efforts and develop new services, positioning itself as a global mid-sized CRO. The consolidation and integration projects are expected to yield efficiency gains.
- Completed Hillcrest, U.K. expansion project.
- Secured two new long-term customer contracts.
- Transition of operations from Blackthorn to Hillcrest by September 2024.
- Extended maturity date of $3.7 million OBRC payable note to July 2025.
- Focus on growing sales and marketing efforts.
- Investments in infrastructure, animal welfare, and safety improvements.
- Expected efficiency gains from consolidation and integration projects.
- The $3.7 million OBRC payable note will start accruing interest at 4.6% per annum from July 2024.
Insights
The news about Inotiv’s Hillcrest, U.K. expansion project being completed is a significant update for investors. The completion of this project enables the company to house two new customers under long-term contracts and consolidate operations from their Blackthorn facility. This consolidation is anticipated to generate efficiency gains through reduced operational redundancy and lower costs associated with maintaining multiple sites. Additionally, these long-term contracts could provide a stable revenue stream, enhancing predictability and financial stability.
The extension of the OBRC payable note also impacts the company's financial position. By extending the maturity date to July 2025, Inotiv gains
For retail investors, these developments suggest that Inotiv is positioning itself for long-term growth and operational efficiency. However, they should consider the impact of interest expenses from the extended note and monitor whether the company can successfully integrate the new customers and realize the projected efficiencies.
The completion of the Hillcrest, U.K. expansion solidifies Inotiv’s position in the contract research organization (CRO) market, particularly within the European region. The investment in upgraded facilities and infrastructure reflects a strategic move to attract and retain high-value clients, especially as the CRO market is highly competitive and quality of facilities can be a differentiator. Moreover, the focus on animal welfare and safety improvements can enhance the company's reputation, aligning with increasing regulatory scrutiny and ethical considerations within the industry.
From a market standpoint, the consolidation of operations from Blackthorn to Hillcrest is a positive step. It suggests a streamlined approach to resource management, which should not only reduce operational costs but also improve service delivery times. Investors should view these moves as positioning Inotiv to leverage new market opportunities more effectively.
Operationally, the completion of the Hillcrest, U.K. expansion marks a critical milestone for Inotiv. Consolidating operations into a central, upgraded facility is expected to bring about significant efficiency gains. The company’s ability to finalize customer occupancy in the expanded facility by the end of June 2024 and complete the transition of Blackthorn operations by September 2024 indicates a well-managed integration process. This should result in smoother operations and improved logistics, as resources can be centralized and utilized more effectively.
The focus on infrastructure, animal welfare and safety improvements underpins Inotiv’s commitment to maintaining high operational standards, which is essential in the CRO industry. These improvements can reduce the risk of operational disruptions and enhance service quality, both of which are critical for maintaining client trust and securing future contracts.
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:
- Hillcrest, U.K. expansion project completed
- Extension of the maturity date of the
$3.7 million OBRC payable note to July 2025
Robert Leasure Jr., President and Chief Executive Officer, commented, “We have substantially completed the Hillcrest, U.K. expansion and improvements, which allows for two new customers with long term contracts, to begin occupying their new space at this facility and for the transfer of our Blackthorn, U.K. operations into Hillcrest. The Hillcrest project has been another significant part of our transformation plan which we initiated in 2022. The transformation has included multiple site closures, significant investments in remaining facilities to support growth, and included investments in infrastructure, animal welfare and safety improvements.
“We are also pleased OBRC agreed to further extend the maturity date of the OBRC payable note. Inotiv will continue to evaluate opportunities to optimize our balance sheet.
“We remain focused on near-term growth initiatives, which include the ramp up of sales and marketing efforts, and the development and growth of new services. Further, we are delighted to be reaching the conclusion of major site consolidation and integration projects, with their expected efficiency gains, plus we continue to invest in animal welfare and safety initiatives. We look forward to realizing the long-term benefits of our investments as part of our efforts to transform the company into a leading global mid-sized CRO.”
Hillcrest, U.K. Facilities Expansion
Inotiv’s Hillcrest, U.K, expansion project is now substantially complete, and the Company is working diligently with new customers to finalize their occupancy in the expanded and upgraded facility by the end of June 2024. With the Hillcrest investments being completed, the Company will also initiate the transition of the operations of the Blackthorn, U.K. facility, to the expanded Hillcrest facility, expected to be complete by September 2024.
Extension of OBRC Payable Note
Inotiv acquired Orient BioResource Center’s ("OBRC") primate quarantine and holding facility, located near Alice, Texas, in 2022. As part of the original purchase consideration, the Company agreed to leave in place a payable note owed by OBRC to the seller in the amount of
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact included in this release, are forward-looking statements, including, but not limited to, statements about the Company’s plans for its Hillcrest and Blackthorn, U.K. facilities and operations, and the Company’s growth initiatives. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “outlook,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from the forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, without limitation, the Company’s inability to execute its plans for its Hillcrest and Blackthorn, U.K. facilities and operations and realize the expected benefits from these actions; the Company’s inability to execute on or achieve its growth initiatives; and those that are described in the Company’s most recent Annual Report on Form 10-K, in the Company’s Quarterly Reports on Form 10-Q, and in other documents that the Company files or furnishes with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this announcement, whether as a result of new information, future events, changes in assumptions or otherwise.
| Company Contact | Investor Relations |
| Inotiv, Inc. | LifeSci Advisors |
| Beth A. Taylor, Chief Financial Officer | Bob Yedid |
| (765) 497-8381 | (516) 428-8577 |
| btaylor@inotivco.com | bob@lifesciadvisors.com |
FAQ
What is the significance of Inotiv's Hillcrest, U.K. expansion?
When was the OBRC payable note maturity date extended to?
What interest rate will the OBRC payable note accrue from July 2024?
How is the completion of the Hillcrest project beneficial for Inotiv?
What are Inotiv's near-term growth initiatives?
